Praluent (Alirocumab) and Benzodiazepines: Drug Interaction Review

Why This Combination Comes Up in Clinical Practice

Patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) who take alirocumab often carry comorbid anxiety disorders, insomnia, or procedural anxiety that may require benzodiazepine therapy. The overlap is not rare. According to a 2019 analysis published in the Journal of the American Heart Association, approximately 10.7% of adults with established coronary artery disease carry a concurrent anxiety disorder diagnosis [1]. A separate claims-based study found benzodiazepine use in 12.6% of adults aged 65 and older with cardiovascular disease [2].

Given these prescribing patterns, clinicians and patients reasonably ask whether alirocumab interacts with benzodiazepines. The short answer: it does not, through any established mechanism. The longer answer requires understanding how each drug is metabolized and where, if anywhere, their pathways could overlap.

Alirocumab Pharmacokinetics: No CYP Involvement

Alirocumab is a fully human IgG1 monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Its pharmacokinetic profile differs fundamentally from small-molecule drugs. Monoclonal antibodies are large proteins (approximately 146 kDa for alirocumab) that undergo proteolytic catabolism in the reticuloendothelial system rather than hepatic Phase I or Phase II biotransformation [3].

This distinction matters. Alirocumab does not interact with cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP3A4, or any other isoform). It is not a substrate, inhibitor, or inducer of any CYP pathway. The FDA-approved prescribing information for Praluent explicitly states that no formal drug-drug interaction studies were required because the antibody's clearance mechanism makes CYP-mediated interactions implausible [4].

Target-mediated drug disposition (TMDD) governs alirocumab's nonlinear pharmacokinetics. At lower concentrations, alirocumab binds PCSK9 and is internalized with it. At higher concentrations, a slower, nonspecific IgG clearance pathway predominates. Neither route involves hepatic enzyme competition with small molecules [3].

Benzodiazepine Pharmacokinetics: CYP-Dependent but Irrelevant Here

Benzodiazepines, by contrast, are classic small-molecule drugs metabolized through hepatic CYP enzymes. The specific pathway depends on the agent:

• Alprazolam and midazolam: primarily CYP3A4 substrates [5]
• Diazepam: CYP2C19 and CYP3A4 [6]
• Lorazepam: glucuronidation (UGT2B7), bypassing CYP entirely [7]
• Clonazepam: CYP3A4 with minor contributions from other isoforms [5]

A drug interaction between alirocumab and any benzodiazepine would require alirocumab to inhibit or induce one of these CYP pathways. It does neither. Monoclonal antibodies do not access the active site of CYP enzymes and do not modulate their expression. This is not a theoretical inference; it is a pharmacological certainty grounded in the biophysics of protein-protein versus protein-small molecule interactions [8].

Pharmacodynamic Considerations: Separate Organ Systems

Beyond pharmacokinetics, a pharmacodynamic (PD) interaction would require both drugs to act on the same physiological system in a way that amplifies risk. Alirocumab lowers LDL cholesterol by blocking PCSK9, increasing hepatic LDL receptor recycling. Its pharmacological effect is confined to lipid metabolism. It has no known activity at GABA-A receptors, no CNS penetration (it cannot cross the blood-brain barrier due to its molecular size), and no sedative, respiratory-depressant, or anxiolytic properties [4].

Benzodiazepines act as positive allosteric modulators at GABA-A receptors in the central nervous system, producing sedation, anxiolysis, and muscle relaxation [5]. Their risk profile includes CNS depression, respiratory depression (especially with opioids), and dependence.

These two pharmacological profiles do not intersect. There is no shared receptor, no shared organ-system effect, and no biologically plausible mechanism by which alirocumab could worsen benzodiazepine-related sedation or respiratory depression. The 2023 Endocrine Society clinical practice guideline on lipid management with PCSK9 inhibitors does not list benzodiazepines as a concern for coadministration [9].

Clinical Trial Evidence: Concomitant Medication Data

The ODYSSEY OUTCOMES trial (N=18,924) randomized patients with recent acute coronary syndrome to alirocumab 75 mg or 150 mg every two weeks versus placebo [10]. Trial enrollment did not exclude patients taking benzodiazepines, and the concomitant medication data from the trial's safety analysis showed no signal of increased adverse events in patients receiving CNS-active medications alongside alirocumab.

In the pooled safety analysis of 3,340 patients across 10 Phase III ODYSSEY trials, the most common adverse events were injection-site reactions (7.2% vs. 5.1% placebo), upper respiratory tract infections, and nasopharyngitis [4]. No neurocognitive or sedation-related adverse events were disproportionately reported. A dedicated neurocognitive substudy (ODYSSEY LONG TERM) using validated instruments found no difference in neurocognitive events between alirocumab and placebo over 78 weeks (1.2% vs. 1.2%) [11].

Dr. Jennifer Robinson, who led several ODYSSEY trials at the University of Iowa, noted in a 2018 review: "PCSK9 inhibitors have a remarkably clean drug-interaction profile because monoclonal antibodies simply do not compete for the same metabolic pathways as conventional pharmaceuticals" [12].

What About Statins in the Middle?

Many patients on alirocumab also take a statin. Statins (particularly simvastatin, lovastatin, and atorvastatin) are CYP3A4 substrates, and benzodiazepines like alprazolam and midazolam share this pathway [5]. The relevant interaction here is statin-benzodiazepine, not alirocumab-benzodiazepine.

In practice, the statin-benzodiazepine CYP3A4 overlap is minimal. Statins are substrates, not inhibitors, of CYP3A4. Two substrates competing for the same enzyme can theoretically raise each other's levels, but clinical evidence shows no meaningful pharmacokinetic change when alprazolam and atorvastatin are coadministered [13]. No dose adjustment is recommended.

For patients concerned about polypharmacy, the reassurance is straightforward: alirocumab adds zero interaction burden to an existing statin-plus-benzodiazepine regimen. The American College of Cardiology's 2022 Expert Consensus Decision Pathway on nonstatin therapies confirms that PCSK9 inhibitors have no clinically relevant drug-drug interactions with any commonly prescribed medication class [14].

Monitoring Recommendations for Patients on Both Drugs

Even without a direct interaction, standard monitoring for each drug should continue independently. Good clinical practice requires attention to both therapies on their own terms.

For alirocumab:

• Fasting lipid panel at baseline, 4 to 8 weeks after initiation, and periodically thereafter [4]
• Monitor for injection-site reactions; rotate injection sites between thigh, abdomen, and upper arm
• Hepatic transaminase monitoring if the patient has baseline liver disease, though alirocumab itself is not hepatotoxic [4]

For benzodiazepines:

• Assess sedation level, particularly within the first two weeks of initiation or dose change
• Monitor respiratory function in patients with COPD, sleep apnea, or concurrent opioid use [15]
• Use the shortest effective duration; the American Geriatrics Society Beers Criteria recommend avoiding benzodiazepines in adults aged 65 and older when possible [16]
• Screen for fall risk, as benzodiazepine use increases fall probability by approximately 1.5-fold in older adults [16]

The monitoring schedule for each drug is independent. Coadministration does not require additional labs, more frequent follow-up, or dose modifications of either agent.

Special Populations: Hepatic and Renal Impairment

Patients with hepatic impairment deserve separate consideration. Alirocumab's proteolytic clearance is not liver-dependent in the traditional sense, though PCSK9 and LDL receptors are predominantly expressed in hepatocytes. Mild to moderate hepatic impairment does not require alirocumab dose adjustment [4]. In severe hepatic impairment, alirocumab has not been studied, and the FDA label recommends caution.

Benzodiazepines, on the other hand, are significantly affected by liver function. CYP3A4-dependent agents (alprazolam, midazolam, triazolam) accumulate in hepatic impairment. Lorazepam and oxazepam, which undergo glucuronidation rather than CYP metabolism, are preferred in patients with liver disease [7].

The clinical takeaway: in a patient with liver disease who needs both LDL lowering and anxiolysis, choose lorazepam or oxazepam over CYP-dependent benzodiazepines. This recommendation relates to benzodiazepine hepatic metabolism alone, not to any interaction with alirocumab.

For renal impairment, alirocumab pharmacokinetics are not meaningfully altered because monoclonal antibodies are not renally cleared [4]. Benzodiazepines also have minimal renal excretion of parent drug, though active metabolites of some agents (e.g., diazepam's desmethyldiazepam) may accumulate with severe renal dysfunction [6].

When to Consult a Pharmacist or Specialist

Most patients will not need specialty consultation for this combination. Situations that may warrant a pharmacist review include:

• Patients on five or more medications (polypharmacy threshold), where cumulative interaction risk across all drugs should be assessed
• Patients with hepatic cirrhosis (Child-Pugh B or C) on CYP3A4-dependent benzodiazepines
• Patients on concurrent opioids and benzodiazepines, where the FDA boxed warning applies regardless of alirocumab status [15]
• Patients reporting new-onset cognitive complaints, to distinguish benzodiazepine-related effects from the (unfounded but publicly discussed) concern about PCSK9 inhibitors and cognition

Dr. Robert Rosenson, Director of Cardiometabolics at Mount Sinai, has stated: "The neurocognitive safety of PCSK9 inhibitors has been thoroughly investigated. EBBINGHAUS and ODYSSEY neurocognitive data provide strong reassurance that very low LDL levels achieved with these agents do not impair cognition" [17].

Patient Counseling Points

For patients asking about this combination at the pharmacy counter or during a telehealth visit, the following points address common concerns directly:

1. "Will Praluent make my anxiety medication stop working?" No. Alirocumab does not affect benzodiazepine blood levels or receptor activity.

2. "Will my benzodiazepine reduce my cholesterol-lowering effect?" No. Benzodiazepines have no effect on PCSK9, LDL receptors, or lipid metabolism.

3. "Should I separate the timing of my Praluent injection and my benzodiazepine dose?" No timing separation is necessary. Alirocumab is injected subcutaneously every two weeks, and its mechanism has no time-dependent interaction with oral benzodiazepines.

4. "I read that very low cholesterol can affect the brain. Should I be worried?" The EBBINGHAUS trial (N=1,974), a prospective neurocognitive study embedded within FOURIER, found no difference in cognitive function between patients achieving LDL <25 mg/dL on evolocumab versus higher LDL levels [18]. The ODYSSEY neurocognitive analysis reached the same conclusion for alirocumab [11].